Entero Therapeutics, Inc. (GRDX) — 10-Q Filings
All 10-Q filings from Entero Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Entero Therapeutics Narrows Losses, Boosts Cash Amid Grid AI Acquisition
— Nov 19, 2025 Risk: high
Entero Therapeutics, Inc. (GRDX) reported a net loss of $3,410,700 for the nine months ended September 30, 2025, a significant improvement from the $5,821,067 n -
Entero Therapeutics Narrows Losses, Faces Cash Crunch
— Aug 14, 2025 Risk: high
Entero Therapeutics, Inc. (GRDX) reported a net loss of $998,271 for the three months ended June 30, 2025, a significant improvement from the $8,807,702 net los -
Entero Therapeutics Q1 2025: Assets Near Liabilities
— May 15, 2025 Risk: medium
Entero Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $4.76 million and total liabilities of $4.75 -
Entero Therapeutics Q3: Assets $4.74M, Liabilities $1.56M
— Nov 13, 2024 Risk: medium
Entero Therapeutics, Inc. reported its third-quarter results for the period ending September 30, 2024. The company had total assets of $4.74 million and total l -
Entero Therapeutics Reports Q2 Loss, Cash Position
— Oct 21, 2024 Risk: medium
Entero Therapeutics, Inc. reported its Q2 2024 results, showing a net loss of $1.56 million on revenue of $0.48 million for the quarter ended June 30, 2024. Thi -
First Wave BioPharma Files 10-Q for Period Ending March 31, 2024
— May 14, 2024 Risk: medium
First Wave BioPharma, Inc. (GRDX) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. First Wave BioPharma, Inc. filed a 10-Q report for the period en
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX